An Anti-Psychotic Drug With its Own Issues: AstraZeneca’s Seroquel – German Patent Tossed
The setback comes in the wake of questions about Seroquel’s heavy prescribing by the U.S. military for off-label uses, as YCharts has reported.
AstraZeneca has struggled more than most drug makers – more, according to this brilliant Forbes analysis, than Pfizer (PFE), GlaxoSmithKline (GSK), Sanofi (SNY) or Johnson & Johnson (JNJ) -- to develop new drugs and replace those with expiring patents.
From the editors of YCharts, which includes the just-released YCharts Pro Platinum for professional investors.
Filed under: Company Analysis